AC8.AU · AusCann Group Holdings Ltd

-

Please sign in to comment on AC8.AU

1 Comment

Admin

4 years, 1 month ago

AusCann Group Holdings Ltd is currently in a long term downtrend where the price is trading 27.9% below its 200 day moving average.

From a valuation standpoint, the stock is 6050.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15832.4.

AusCann Group Holdings Ltd's total revenue sank by 64.2% to $92K since the same quarter in the previous year.

Its net income has dropped by 34.3% to $-5M since the same quarter in the previous year.

Finally, its free cash flow grew by 68.1% to $-2M since the same quarter in the previous year.

Based on the above factors, AusCann Group Holdings Ltd gets an overall score of 1/5.

Exchange	AU
CurrencyCode	AUD
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
ISIN	AU000000AC89

PE Ratio	0.0
Target Price	None
Market Cap	18M
Beta	0.8
Dividend Yield	None

ABOUT

AusCann Group Holdings Ltd

AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.

AC8.AU · AusCann Group Holdings Ltd

-

AusCann Group Holdings Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest AusCann Group Holdings Ltd using a moving average strategy